Taking place July 17-18, 2017, ExL’s 2017 Trial Protocol Optimization and Design Congress will explore the complex relationship protocol design has with clinical trial success. Attendees will discover new techniques, hear from industry thought leaders and examine case studies on protocol optimization.
Clinical protocols are the framework for a clinical trial. From the amount of samples to take from a patient to the type of patients required for the study, they ensure every detail, incident or outcome is planned for. Over the last few years, protocols have been under tremendous scrutiny for their lack of insight, flexibility and feasibility. Due to these issues, protocol optimization has made a resurgence as a major innovation in the pharmaceutical industry. Companies, sites and CROs are beginning to notice how inflated protocols have gotten, how much protocol amendments are costing studies, and how protocols are unrealistic for patients and practitioners. Optimization will improve patient care and outcomes, site performance and recruitment, and — ultimately — the bottom line for drug development.
The 2017 Trial Protocol Optimization and Design Congress will bring together sites, pharma companies, CROs and other stakeholders in the protocol-writing process to discuss how the industry should change their policies and procedures. With topics on inclusion/exclusion, advisory boards, training for protocol writers and patient feasibility, the congress will foster a space the industry can build upon and make changes to improve all aspects of clinical trial design and planning.